Stock ALVO ALVOTECH
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Alvotech

Equities

ALVO

LU2458332611

End-of-day quote Nasdaq
Other stock markets
 23:00:00 14/05/2024 BST 		5-day change 1st Jan Change
13.35 USD 0.00% Intraday chart for Alvotech +0.45% +16.29%
03:57pm Alvotech Signs Commercialization Deal for Prolia, Xgeva Biosimilar MT
03:21pm Alvotech and Dr. Reddy's Partner to Commercialize Biosimilar Candidate Denosumab MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alvotech : and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
PU
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
GL
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
AQ
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
GL
Alvotech S.A. Annual General Meeting to be held June 7, 2024
GL
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
AQ
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
GL
Alvotech : General Meeting Alvotech - Convening Notice (AGM 2024)
PU
Alvotech Announces Positive Topline Results From Confirmatory Clinical Study For Its Proposed Golimumab Biosimilar
AQ
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
GL
Alvotech - U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-FreeInterchangeable Biosimilar to Humira
AQ
Alvotech And Teva's Selarsdi™ (ustekinumab-aekn), Biosimilar To Stelara® Approved By FDA
AQ
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
GL
FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar
AQ
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi
AQ
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
GL
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira
AQ
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
GL
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
AQ
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALVO Stock
  4. News Alvotech
  5. Press Releases